ReviewCell insight2026
Hydrophobic tagging: A promising paradigm for targeted protein degradation.
Review in Cell insight, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hydrophobic Tag Protein Degraders: An Emerging Therapeutic Strategy for Cancer.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Targeted protein degradation dismantles undruggable targets to reverse immune evasion and therapy resistance in cancer.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeted protein degradation (TPD) has emerged as a groundbreaking therapeutic strategy, overcoming the limitations of traditional occupancy-driven pharmacology. Among TPD strategies, hydrophobic tag (HyT) technology exemplifies this paradigm shift by hijacking cellular protein quality control mechanisms for precise protein elimination. Structurally, HyT molecules integrate a target-specific ligand with a hydrophobic domain that emulates misfolded protein surfaces, facilitating selective recruitment of chaperone systems (e.g., heat shock protein 70, HSP70) and ubiquitin-proteasome system (UPS) activation, circumventing the E3 ligase dependency inherent to proteolysis-targeting chimera (PROTAC) systems. This innovative strategy offers distinct therapeutic benefits, including enhanced tissue-specific accumulation and the capacity to overcome resistance mechanisms. This review highlights the important advances in this rapidly growing field and critical limitations encountered in developing HyT degraders by analyzing the current status and representative examples of HyTs in degrading diverse pathogenic proteins, including oncogenic drivers (e.g., signal transducer and activator of transcription 3, STAT3), neurodegenerative aggregates (tau, α-synuclein), and viral envelope proteins. The critical developments, including the rational design of hydrophobic motifs and possible mechanistic insight into the degradation process of HyTs, have also been discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.